Ovarian Cancer Drugs Market Global Industry Analysis and Growth By 2020 – Size, Share, Trends, Opportunities, Top 5 Key Players and Regional Forecast Up To 2026

Ovarian cancer is a type of cancer that mainly occurs in the reproductive part of the women i.e. ovary. This condition is characterized by abnormal growth of cell in the ovaries, which has the potential to destroy other body parts such as abdomen layers, the lining of the bowel and bladder, lymph nodes, and liver. Inflating, pelvic ache, abdominal puffiness, and loss of appetite are some of the major symptoms of ovary cancer.

Request for the trending sample of this report: https://www.coherentmarketinsights.com/insight/request-sample/164

The risk of ovarian cancer is higher among women who have ovulated more over their lifetime, which can also include females who have begun ovulating at a very young age. According to the American Cancer Society, around 10% of ovarian cancer cases are related to inherited genetic risk. Women with mutations in BRCA1 or BRCA2 genes have a 50% chance of developing breast or ovarian cancer. Ovarian carcinoma is the most common ovarian cancer that accounts for 95% of cases, globally.

The growth of ovarian cancer drugs is supported by the rising aging population in the U.S. and U.K.

A growing number of ovarian cancer cases recorded over the recent past is creating a highly conducive environment for the growth of the ovarian cancer drugs market. According to American Cancer Society, in 2016, around 22,280 new cases of ovarian cancer were diagnosed, leading to 14,240 deaths in the U.S. According to the Surveillance, Epidemiology and End Results (SEER) Program of the National Cancer Institute data, an increase in all new cancer cases is recorded, with ovarian cancer accounting for 1.3% of the incidence rate, and 2.4% of all related deaths, in 2016. The number of new ovarian cancer cases accounts for 11.9 per 100,000 women, and the total deaths account for 7.5 per 100,000 women, annually. According to World Cancer Research Fund International data based on the highest rate of ovarian cancer by country: Fiji, age-standardized rate per 100,000 is 14.9, followed by Latvia and Bulgaria with an age-standardized rate per 100,000 is 14.2 and 14.0, respectively. The U.K. stands tenth, with age-standardized rate per 100,000 pegged at 11.7. Around 58% of ovarian cancer cases are diagnosed in emerging economies, with the highest incidence rate recorded in Africa and the Asia Pacific. In the U.K., around 46% of women diagnosed with ovarian cancer, survive for around five years or more following the onset of the disease. According to the Australian Government, Cancer Australia, as of 2017, 1,580 new ovarian cancer cases are estimated to be diagnosed, accounting for 2.5% of ovarian cancer cases among all new cancer cases in the country. This is estimated to result in 1,047 deaths in 2017. Thus, the ovarian cancer drug industry is expected to gain significant traction in developed regions, in the near future.

Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!

Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/164

Ovarian Cancer Drugs Market Taxonomy

The global ovarian cancer drug market is segmented based on chemotherapy drugs, end-users, and geography.

Based on chemotherapy drugs, ovarian cancer drugs are segmented into:

• Carboplatin
• Cisplatin
• Docetaxel
• Paclitaxel
• Other Medication (Cyclophosphamide, Doxorubicin, Gemcitabine, Oxaliplatin, and Topotecan).

Based on end-user, the market is segmented into:

• Hospitals
• Ambulatory Surgical Centers
• Clinics

Table of Contents

1. Research Objectives and Assumptions
   • Research Objectives
   • Assumptions
   • Abbreviations
2. Market Purview
   • Report Description
     • Market Definition and Scope
   • Executive Summary
     • Market Snippet, By Product Type
     • Market Snippet, By Application
     • Market Snippet, By End User
     • Market Snippet, By Region
   • Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
   • Market Dynamics
     • Drivers
     • Restraints
     • Market Opportunities
   • Impact Analysis
   • Key Developments
   • PEST Analysis
4. Global Ovarian Cancer Drugs – Impact of Coronavirus (Covid-19) Pandemic
   • COVID-19 Epidemiology
   • Safety Syringes for COIVD-19 Vaccines
5. Global Ovarian Cancer Drugs Market, By Product Type, 2016 – 2027, (US$ Mn)
6. Global Ovarian Cancer Drugs Market, By Application, 2016 – 2027, (US$ Mn)
7. Global Ovarian Cancer Drugs Market, By End User, 2016 – 2027, (US$ Mn)
8. Global Ovarian Cancer Drugs Market, By Region, 2016 – 2027, (US$ Mn)
   • Introduction
     • Market Share Analysis, By Region, 2020 and 2027 (%)
     • Y-o-Y Growth Analysis, For Regions, 2017–2027
   • North America
     • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
     • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
     • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
     • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
       • U.S.
       • Canada
   • Latin America
     • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
     • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
     • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
     • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
       • Brazil
       • Mexico
       • Argentina
       • Rest of Latin America
   • Europe
     • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
     • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
     • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
     • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
       • Germany
       • U.K.
       • France
       • Italy
       • Spain
       • Russia
       • Rest of Europe
   • Asia Pacific
     • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
     • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
     • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
     • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
       • China
       • India
       • Japan
       • Australia
       • South Korea
       • ASEAN
       • Rest of Asia Pacific
   • Middle East
     • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
     • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
     • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
     • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
       • GCC
       • Israel
       • Rest of Middle East
   • Africa
     • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
     • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
     • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
     • Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Mn)
       • South Africa
       • Central Africa
       • North Africa

To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/ovarian-cancer-drugs-market-164

High prevalence of ovarian cancer among women over 60 years in the U.S. and U.K. have been reported recently

Regional segmentation of the global ovarian cancer drugs market by Coherent Market Insights comprises North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America accounts for the largest market share, mainly due to the strong presence of major players and the rising adoption of advanced medical technologies across countries such as the U.S. and Canada. According to the American Cancer Society, an estimated 22,440 women would receive a new diagnosis of ovarian cancer and around 14,080 women will die from ovarian cancer in 2017 in the U.S. alone. Ovarian cancer is the fifth most prevalent cancer among women, which accounts for a high percentage of deaths when compared to other cancer related to reproductive system cancer. It is stated that 1 in 75 women are at risk of contracting ovarian cancer and fatalities related to the disease are pegged at 1 in 100. The prevalence of ovarian cancer is usually low among women under 40 years of age. According to the American Cancer Society, most of the ovarian cancer cases are reported among women aged 60 years and above. According to Cancer Research UK, in 2014, 7,378 new cases of ovarian cancer were reported in the country, of which around 53% of cases diagnosed were among females aged 65 years and above.

A combinational drug approach is a novel approach in the ovarian cancer drugs market

Major players engaged in the ovarian cancer drugs market include Bristol Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Novogen, Inc., Genentech Inc., Aetera Zenteris Inc., Boehringer Ingelheim GmbH, and F. Hoffman-La Roche Ltd. Major companies in this market are constantly working towards introducing innovative products and lowering production costs to enhance profitability. For instance, Roche’s blockbuster drug Avastin (bevacizumab) used in combination with carboplatin and paclitaxel is being used to treat ovarian cancer.

Request discount for this report @ https://www.coherentmarketinsights.com/insight/request-discount/164

Key Developments

Research and development related to the diagnosis and treatment of ovarian cancer are projected to offer lucrative opportunities for market players. For instance, in August 2019, researchers from The George Washington University School of Medicine and Health Sciences, U.S. identified ovarian cancer drug resistance protein that needs to be blocked for the treatment of patients with platinum-resistant ovarian cancer.

Moreover, in July 2019, researchers from the University College London, in collaboration with research centers in Germany, Italy, Norway, and the Czech Republic, found a link between lower levels of lactobacilli in the vagina and the presence of ovarian cancer or BRCA1 mutations in women aged under 50.

Similarly, in February 2018, researchers from Roswell Park Cancer Institute in Buffalo, New York, found that paternal genes may influence ovarian cancer risk.

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837